Comparative Pharmacology
Head-to-head clinical analysis: IMIPRAMINE HYDROCHLORIDE versus SILENOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMIPRAMINE HYDROCHLORIDE versus SILENOR.
IMIPRAMINE HYDROCHLORIDE vs SILENOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their synaptic concentrations. Also has anticholinergic, antihistaminergic, and alpha-1 adrenergic blocking effects.
Selective histamine H1 receptor antagonist; promotes sleep by antagonizing central histaminergic neurotransmission.
Initial 75 mg/day orally in divided doses, increase to 150-200 mg/day; maximum 300 mg/day. For maintenance, 50-150 mg/day orally.
6 mg orally once daily at bedtime, not to exceed 6 mg/day.
None Documented
None Documented
Terminal half-life 11-25 hours (mean ~20 h); clinical context: steady-state achieved in ~1 week, dosing adjustment needed in hepatic impairment
Terminal elimination half-life is approximately 10 hours (range 8-15 hours) in healthy adults; prolonged in elderly and hepatic impairment.
Renal (70% as metabolites, <5% unchanged), biliary/fecal (30%)
Primarily renal (approximately 60% as unchanged drug and metabolites), with 30% fecal elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant